Orum Therapeutics Announces Three Presentations At AACR 2023
Poster Title:
PD-1-Cbl-bi TPS² preclinical poster
A novel antibody-enabled Dual-precision Targeted Protein Stabilization (TPS²) that augments anti-tumor immune response by targeting Cbl-b inhibitor to exhausted T cells while blocking checkpoint molecule, PD-1
ORM-6151: A first-in-class CD33-antibody enabled GSPT1 degrader for AML
ORM-5029 predictive biomarker poster
Development of RNAscope multiplex-based assay for exploratory pharmacodynamic biomarkers assessment in breast cancer patients from Phase I clinical trial of ORM-5029, a potent GSPT1 degrader
Date and Time: 4/17/2023, 9:00 AM - 12:30 PM ET
